Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs OGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

PTN Overall Winner 6-Pillar Tally: PTN 4 – 1 OGEN (1 Tie) Matrix Metrics: PTN 7 – 3 OGEN

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas OGEN carries 38.8/100 (SELL) at $0.20 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While OGEN currently prints a higher short-term Unified Composite Score (38.8/100 SELL vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. -91.3% YoY).
  • Defensive Composite Rating Caution: Although PTN compares more favorably head-to-head, both PTN (31.5/100 SELL) and OGEN (38.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile OGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs OGEN
PTN US Equity Head-to-Head Winner
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
OGEN NYSE American
Oragenics Inc.
Pharmaceutical Preparations
$0.20
-1.49% 1D
Market Cap $906,903
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 153% Vol
Unified Composite Score
38.8 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.5%), weak momentum, RSI 14
RSI-14: 14.1 · SMA20: $0.36 · SMA50: $0.43

6-Pillar Scorecard Institutional Category Breakdown (PTN 4 – 1 OGEN)

Columns: Metric · PTN · OGEN
1. Valuation Multiples PTN
Forward P/E 42.9x N/M
Trailing P/E 42.9x N/M
PEG Ratio 1.62x N/M
EV / Revenue 0.1x N/M
2. Growth & Scale PTN
Revenue Growth (YoY) -80.1% -91.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M N/A
Market Cap $11.1M $906,903
3. Profitability & Quality OGEN
Gross Margin 6.2% N/A
Operating Margin -65.7% 0.0%
Net Profit Margin -63.5% 0.0%
Return on Equity (ROE) -877.5% -1307.1%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$15M N/A
Cash Flow Margin -113.6% N/A
Net Cash / Leverage $9.9M Net Cash $1.94 Book/Sh · -1307.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (7) vs OGEN (3)
Institutional Metric PTN OGEN Criterion Row Edge
Market Capitalization
Scale
$11.1M $906,903 Larger Scale PTN
Trailing P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Forward P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Revenue Growth (YoY)
Growth
-80.1% -91.3% Higher Growth PTN
Operating Margin (TTM)
Profitability
-65.7% 0.0% Higher Margin OGEN
Net Profit Margin
Profitability
-63.5% 0.0% Higher Margin OGEN
Return on Equity (ROE)
Capital Efficiency
-877.5% -1307.1% Higher ROE PTN
52-Week Range Position
Momentum
6% ($5–$31) 3% ($0–$1) Stronger Trend PTN
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 1.19β · 153% Vol Lower Realized Risk PTN
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 38.8 / 100 (SELL) Higher Composite OGEN
Trailing 12M Revenue (USD)
Operating Scale
$13M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) N/A ($1.94 Book/Sh · -1307.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +56.21 pp
PTN: +1.74% · OGEN: -54.47%
3M Horizon PTN +22.02 pp
PTN: -41.72% · OGEN: -63.74%
6M Horizon PTN +5.52 pp
PTN: -59.81% · OGEN: -65.33%
1Y Horizon PTN +39.34 pp
PTN: -43.29% · OGEN: -82.63%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PTN Revenue OGEN Revenue PTN Op. Margin OGEN Op. Margin Margin Leader
FY2018 $70M N/A 38.6% N/A PTN
FY2019 $60M N/A 59.3% N/A PTN
FY2020 $0M N/A -20007.6% N/A PTN
FY2021 N/A $0M N/A -18130.3% OGEN
FY2022 $0M $0M -2491.6% -10964.6% PTN
FY2023 $0M $0M -668.7% -55519.9% PTN
FY2024 $0M N/A -501.0% N/A PTN
FY2026 $10M N/A -65.7% N/A PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
OGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $906,903 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs OGEN Key Questions & Quantitative Answers

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Oragenics Inc. (OGEN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas OGEN carries 38.8/100 (SELL) at $0.20 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OGEN currently prints a higher short-term Unified Composite Score (38.8/100 SELL vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. -91.3% YoY). Defensive Composite Rating Caution: Although PTN compares more favorably head-to-head, both PTN (31.5/100 SELL) and OGEN (38.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile OGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTN leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with OGEN at -91.3% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), PTN cumulative revenue shifted -85.7% while OGEN shifted N/A. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OGEN.

PTN screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas OGEN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus OGEN (-1307.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, OGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 153% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.